Business
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19 in Washington, D.C. Accepted abstracts and the full preliminary program is available on the ASGCT website. “We look forward to reporting data at ASGCT 2022 that showcases our broad range of gene therapy expertise that is shaping our portfolio strategy and therapeutic pipeline,” said Al Sandrock, M.D., Ph.D., CEO of Voyager Therapeutics. “Among the notable findings to be presented are new data from Voyager’s TRACER™ AAV capsids, including a novel AAV9-derived capsid family with tropism for glial cells, updated findings from our novel vectorized antibody approach designed to activate innate immune system to destroy metastatic breast cancer tumors, and results from our Tau, SOD1 ALS, and GBA1 programs.” Details for the oral and poster presentations are as follows. Oral Presentations Monday, May 16 CNS Penetrant AAV Vectors Encoding HER2 Antibodies Reduce Tumor Burden in Models of Breast Cancer Brain Metastasis Dan Laks, Ph.D., Senior Scientist I, Program LeadSummary: A CNS-targeted, TRACER-generated AAV capsid was used to deliver broad brain expression of a vectorized HER2 antibody, which activated the innate immune response with increased tumor-proximal natural killer cells, proliferating microglia, and dendritic cells, and significantly reduced tumor burden in multiple mouse models.Session: AAV Preclinical CNS Gene TherapyLocation & Time: Room 204, 5:15 p.m. – 5:30 p.m. ESTAbstract Number: 63 Thursday, May 19 Directed Evolution of AAV9 Peptide Display Libraries Identifies a Family of Cross-Species Variants with Enhanced Brain Tropism in Non-Human Primates and Mice Following Systemic AdministrationTyler Moyer, Ph.D., Scientist II, Capsid DiscoverySummary: A novel, TRACER-generated AAV9 capsid family achieved 50-fold better transduction in mice and 60-fold better transduction in macaques compared to conventional AAV9 with a unique tropism for glial cells. Session: Novel AAV Capsids for the Brain, Eye and KidneyLocation & Time: Ballroom A, 11:00 a.m. – 11:15 a.m. ESTAbstract number: 1198 Pos...